18
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Quantification of Retinal Microvascular Density in Optical Coherence Tomographic Angiography Images in Diabetic Retinopathy

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Importance

          Quantitative measurements based on optical coherence tomographic angiography (OCTA) may have value in managing diabetic retinopathy (DR), but there is limited information on the ability of OCTA to distinguish eyes with DR.

          Objective

          To evaluate the ability of measurements of retinal microvasculature using OCTA to distinguish healthy eyes from eyes with DR.

          Design, Setting, and Participants

          In this prospective cross-sectional study, OCTA was used to examine the eyes of participants with type 2 diabetes with or without DR and the eyes of participants without diabetes from September 17, 2015, to April 6, 2016. Density maps based on superficial retinal layer (SRL) and deeper retinal layer (DRL) images were generated after a method to remove decorrelation tails was applied to the DRL images.

          Exposures

          Both eyes of each participant were examined by means of a 3-mm OCTA scan and 7-field fundus photography using the Diabetic Retinopathy Severity Scale.

          Main Outcomes and Measures

          Two measures were examined: perfusion density, based on the area of vessels, and vessel density, based on a map with vessels of 1-pixel width. The size of the foveal avascular zone was also calculated automatically, and so was the area under the receiver operating characteristic curve.

          Results

          A total of 50 eyes from 26 participants with diabetes (10 women and 16 men; mean [SD] age, 64.9 [7.5] years) and 50 healthy eyes from 25 participants without diabetes (14 women and 11 men; mean [SD] age, 64.0 [7.1] years) were imaged. All participants were white. Vessel density measured in the SRL had the highest area under the receiver operating characteristic curve (0.893 [95% CI, 0.827-0.959]), compared with perfusion density in the SRL (0.794 [95% CI, 0.707-0.881]), foveal avascular zone area (0.472 [95% CI, 0.356-0.588]), and vessel density in the DRL (0.703 [95% CI, 0.601-0.805]). Vessel density in the SRL negatively correlated with best-corrected visual acuity ( r = –0.28; P = .05) and severity of DR ( r = –0.46; P = .001). Density metrics correlated with age. No correlation was detected between vascular density or foveal avascular zone metrics and hemoglobin A 1C or duration of diabetes.

          Conclusions and Relevance

          Vessel density measured by OCTA provides a quantitative metric of capillary closure that correlates with severity of DR and may allow staging, diagnosis, and monitoring that do not require subjective evaluation of fundus images.

          Abstract

          This cross-sectional study evaluates the ability of measurements of retinal microvasculature using optical coherence tomographic angiography to distinguish healthy eyes from eyes with diabetic retinopathy.

          Key Points

          Question

          Can quantitative metrics based on optical coherence tomographic angiography be used to distinguish healthy eyes from diabetic eyes?

          Findings

          In this cross-sectional study, vessel density measured in the superficial retina distinguished healthy eyes from diabetic eyes and correlated with clinically relevant measures such as stage of disease, visual acuity, and central retinal thickness.

          Meaning

          These data suggest that quantification of the microvasculature in the retina correlates with existing clinical observations and may be an improvement over the current standard because it is objective and continuous rather than subjective and categorical.

          Related collections

          Author and article information

          Journal
          JAMA Ophthalmol
          JAMA Ophthalmol
          JAMA Ophthalmol
          JAMA Ophthalmology
          American Medical Association
          2168-6165
          2168-6173
          16 March 2017
          13 April 2017
          April 2017
          13 April 2018
          : 135
          : 4
          : 370-376
          Affiliations
          [1 ]Research and Development, Carl Zeiss Meditec, Inc, Dublin, California
          [2 ]Associação para Investigação Biomédica em Luz e Imagen, Coimbra, Portugal
          Author notes
          Article Information
          Accepted for Publication: January 8, 2017.
          Corresponding Author: Mary K. Durbin, PhD, Research and Development, Carl Zeiss Meditec, Inc, 5160 Hacienda Dr, Dublin, CA 94568 ( mary.durbin@ 123456zeiss.com ).
          Published Online: March 16, 2017. doi:10.1001/jamaophthalmol.2017.0080
          Author Contributions: Drs Durbin and Cunha-Vaz had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
          Study concept and design: Durbin, Cunha-Vaz.
          Acquisition, analysis, or interpretation of data: All authors.
          Drafting of the manuscript: Durbin, Santos, Lopes, Neves.
          Critical revision of the manuscript for important intellectual content: Durbin, An, Shemonski, Soares, Cunha-Vaz.
          Statistical analysis: Durbin, Santos, Lopes.
          Obtained funding: Durbin.
          Administrative, technical, or material support: Durbin, An, Soares, Neves.
          Study supervision: Durbin, Cunha-Vaz.
          Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Drs An, Durbin, and Shemonski are employed by Carl Zeiss Meditec, Inc. No other disclosures were reported.
          Funding/Support: Carl Zeiss Meditec, Inc, provided the AngioPlex device and annual research support for Dr Cunha-Vaz to perform the study described here.
          Role of the Funder/Sponsor: The funding source had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
          Article
          PMC5470403 PMC5470403 5470403 eoi170008
          10.1001/jamaophthalmol.2017.0080
          5470403
          28301651
          9de1e88f-c3de-439e-a752-c2c551b04744
          Copyright 2017 American Medical Association. All Rights Reserved.
          History
          : 14 September 2016
          : 5 January 2017
          : 8 January 2017
          Funding
          Funded by: Carl Zeiss Meditec, Inc
          Categories
          Research
          Research
          Original Investigation
          Online First

          Comments

          Comment on this article